Nasus Pharma files to sell up to $8.5 million in shares via ATM offering
The Israeli intranasal drug developer set terms with BTIG on September 18, 2026, for stock sales tied to its epinephrine program NS002.
SEC filing
Latest
3 stories
Friday, September 18
Wednesday, August 19
Nasus Pharma CFO Eyal Rubin to resign, interim successor named
The company said Rubin will leave to pursue an opportunity outside life sciences, with Director of Finance Oren Elmaliach stepping in as interim CFO.
SEC filing
Tuesday, July 28
Nasus Pharma names Brendan P. O'Grady CEO, succeeding Dan Teleman
The intranasal drug developer said O'Grady will focus on NS002 commercialization ahead of a planned pivotal trial and 2027 data readout.
SEC filing